A study from the Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA; and College of Physicians and Surgeons, Columbia University, New York, USA shows that “A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.” This study was published in the 9 Feb 2015 issue of the Journal “Cancer cell” (the no.1 journal in cancer biology with an impact factor of 23.893) by Prof Domingo-Domenech J, Vidal SJ, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Vitamin-based therapy stalls metastatic Prostate cancer progression: Vitamin-E (α-Tocopherol) suppresses GATA2-IGF2 axis and halts the progression of prostate cancer.
Significance: Given that prostate cancer is/had: (1) one of the most frequently diagnosed cancer in males; (2) the sixth leading cause of cancer death in males globally; and (3) caused 256,000 deaths in 2010, there is an urgent need to find an effective therapy for prostate cancer. This study suggests, for the first time, that ATRA, by increasing the expression of its target gene, it may decrease the expression of its target gene IGF2. Thereby, it may inhibit the GATA2-IGF2 axis in aggressive prostate cancer. Thus, pharmacological formulations encompassing “ATRA or its analogues” may be used to inhibit the progression of prostate cancer.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Vitamin-based therapy stalls metastatic Prostate cancer progression: ATRA (A vitamin-A derivative) suppresses GATA2-IGF2 axis and halts the progression of prostate cancer, 13/April/2015, 13.45, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation